

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/031592-2024>

Not applicable

## **Licensing Spironolactone for Acne in Women**

NHS England

F14: Notice for changes or additional information

Notice identifier: 2024/S 000-031592

Procurement identifier (OCID): ocds-h6vhtk-045808

Published 2 October 2024, 4:31pm

### **Section I: Contracting authority/entity**

#### **I.1) Name and addresses**

NHS England

7-8 Wellington Place

Leeds

LS1 4AP

#### **Contact**

Leigh Parker

#### **Email**

[leigh.parker1@nhs.net](mailto:leigh.parker1@nhs.net)

#### **Country**

United Kingdom

#### **Region code**

UK - United Kingdom

**Internet address(es)**

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

---

## Section II: Object

### II.1) Scope of the procurement

#### II.1.1) Title

Licensing Spironolactone for Acne in Women

Reference number

C301713

#### II.1.2) Main CPV code

- 85100000 - Health services

#### II.1.3) Type of contract

Services

#### II.1.4) Short description

NHS England requires a supplier to apply for a major (type II) MHRA Marketing Authorisation variation for spironolactone. The variation is to add a new indication to the current licence (marketing authorisation) for treating acne in women. The Successful Supplier would need to prepare a dossier for the MHRA including a Risk Management Plan, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data.

To register an interest in responding to this opportunity and obtain a copy of the tender documents please go to: <http://health.atamis.co.uk>. All communications and Request for Information submissions will be conducted via Atamis. The portal can be accessed at any time of the day and it is free to register.

---

## Section VI. Complementary information

### VI.6) Original notice reference

Notice number: [2024/S 000-028524](#)

---

## Section VII. Changes

### VII.1.2) Text to be corrected in the original notice

Section number

II.1.1.1

Instead of

Text

Licensing Spironolatone for Acne in Women

Read

Text

Licensing Spironolactone for Acne in Women